Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Item
http://www.wikidata.org/entity/Q37723328
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Dose finding with longitudinal data: simpler models, richer outcomes.A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.Challenges of clinical trial design for targeted agents against pediatric leukemias.Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicitiesICH S9: Developing anticancer drugs, one year later.Pharmaceutical differences between block copolymer self-assembled and cross-linked nanoassemblies as carriers for tunable drug release.Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.The cytotoxic and growth inhibitory effects of palladium(II) complexes on MDA-MB-435 cells.Targeting cancer with peptide aptamers.Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation.Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
P2860

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Item
http://www.wikidata.org/entity/Q37723328
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current challenges for the ear ...... f molecularly targeted agents.
@en
Current challenges for the ear ...... f molecularly targeted agents.
@nl
type
label
Current challenges for the ear ...... f molecularly targeted agents.
@en
Current challenges for the ear ...... f molecularly targeted agents.
@nl
prefLabel
Current challenges for the ear ...... f molecularly targeted agents.
@en
Current challenges for the ear ...... f molecularly targeted agents.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Current challenges for the ear ...... f molecularly targeted agents.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698